‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

Re­gen­eron might be ready for com­pe­ti­tion with its block­buster drug Eylea, but it’s not clear that in­vestors are.

On Thurs­day morn­ing, the biotech’s lead­er­ship field­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER